Recipient’s Name

Address line 1

Address line 2

Address line 3

Country

Date

Dear XXXXXX XXXXXXXXX,

**As COVID-19 restrictions lift and life returns to a new normal for many in society, the lives of immunocompromised blood cancer patients remain at risk since more than 1 in 4 do not produce antibodies against COVID-19 even after a full course of vaccinations.**

These patients carry a high risk of infection, severe disease course and death, and suffer from psychological side-effects due to prolonged shielding.

To help drive change in health policy and protect those who can't protect themselves the

**International Covid-19 Blood Cancer Coalition calls on YOU to:**

* Ensure access to pre- and post-exposure prophylaxis and antivirals for high-risk IC blood cancer patients.
* Make access to vaccinations and additional doses a policy for these patients.
* Facilitate access to fast response COVID-19 testing for high-risk IC patients.
* Promote access to psychological and psycho-oncological services specifically for IC blood cancer patients who need to continue shielding despite the relaxation of public safety measures.
* Enable and encourage specific research about Covid-19 and IC blood cancer patients and existing and future antiviral and monoclonal antibody treatments.
* Accelerate clinical trials for these next-generation antibody and antiviral treatments.

Thank you for considering the needs of this large population and helping to protect those who cannot protect themselves.

Yours sincerely,

XXXXXXXX

**Statement of endorsement**

[In their joint statement](https://www.icbcc.info/patient-impact-statement/), more than 70 researchers, clinicians, patient organisations and medical societies urge stakeholders to consider IC blood cancer patients in health policy decisions.

|  |
| --- |
| **About the ICBCC:**  A multi-stakeholder coalition, the International COVID-19 Blood Cancer Coalition, calls upon decision-makers  in health policy and care to enable access to IC blood cancer patients to life-saving therapies, and to drive change to accommodate the needs of those patients in general and particularly during the COVID-19 pandemic. |